Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid - Seite 2
About Ray Therapeutics
Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate RTx-015 in retinitis pigmentosa, a degenerative
retinal disease with significant unmet medical need. The company’s mission is to use optogenetics to restore vision, independent of genetic mutation for patients with inherited retinal diseases.
Ray Therapeutics is based in San Francisco, California. For additional information, visit www.raytherapeutics.com.
Forward-looking Statements
Statements contained in this press release regarding events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements include but are not limited to statements regarding the potential benefits of AAV.7m8 as a potent capsid. Actual results could differ materially from those anticipated
in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict
the outcome of clinical trials; regulatory uncertainties; the results of early clinical trials not always being predictive of future clinical trials and results; and the potential for future
complications or side effects in connection with use of AAV.7m8. Additional risks and uncertainties facing Adverum are set forth under the caption “Risk Factors” and elsewhere in Adverum’s
Securities and Exchange Commission (SEC) filings and reports, including Adverum’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 filed with the SEC on May 11, 2023. All
forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.
Adverum Corporate, Investor and Media Inquiries
Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: areddi@adverum.com
Lesen Sie auch
Ray Therapeutics Media Inquiries
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com